Carcinoma, Squamous Cell of Head and Neck Clinical Trial
Official title:
A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy in Medical Practice
The purpose of the study is to determine whether prophylactic gastrostomy leads to less treatment interruption and provide better quality of life in head and neck cancer patients receiving chemoradiotherapy.
Nutritional status is one of the essential factor to determine outcome of chemoradiotherapy
in head and neck cancer patients. Almost all these patients develop mucositis during the
treatment, which usually leads to treatment interruptions and affects the efficacy of the
treatment. Prophylactic gastrostomy has been accepted for these patients with improvement of
quality of life. However, there is no prospective study confirming superiority of such
treatment.
The investigators enrolled head and neck cancer patients who had the plan of
chemoradiotherapy. The patients will be informed about both treatment arms and will decide
the arm that they preferred. The treatment interruptions, body weight and nutritional status
will be assessed every 2 weeks during treatment period.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02113878 -
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
|
Phase 1 | |
| Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
| Terminated |
NCT02277184 -
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT01080066 -
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
|
N/A | |
| Completed |
NCT02585973 -
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
|
Phase 1 | |
| Completed |
NCT01836029 -
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Active, not recruiting |
NCT03715946 -
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03088059 -
Biomarker-based Study in R/M SCCHN
|
Phase 2 | |
| Recruiting |
NCT06003231 -
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
|
Phase 2 | |
| Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
| Completed |
NCT02242916 -
State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study
|
N/A | |
| Terminated |
NCT02655068 -
Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03509012 -
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02296684 -
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03799744 -
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT03109158 -
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03485209 -
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
|
Phase 2 | |
| Completed |
NCT01307267 -
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
|
Phase 1 | |
| Terminated |
NCT02822482 -
Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
|
Phase 1/Phase 2 | |
| Completed |
NCT02101034 -
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
|
Phase 1/Phase 2 |